NorthStar Medical Radioisotopes has received a custom-built IBA Rhodotron TT 300-HR electron beam accelerator to its new Ac-225 Production facility, the organization announced recently. According to a release, the accelerator…
NorthStar Medical Radioisotopes is collaborating with Inhibrx, a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, the company announced recently. According to a release, the…
NorthStar Medical Radioisotopes has broken ground on a new facility that will house a planned contract development and manufacturing business unit called Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), the…
NorthStar Medical Radioisotopes has been awarded $37 million in cooperative agreement funds with the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), the company announced today. According to a…
NorthStar Medical Radioisotopes and GE Healthcare signed an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States, NorthStar announced recently. According to a release,…
NorthStar Medical Radioisotopes has received two custom-built IBA Rhodotron TT 300-HE electron beam accelerators at its facility, the company announced recently. According to a release, the accelerators are critical components…
NorthStar Medical Radioisotopes and Ion Beam Applications (IBA), a provider of proton therapy solutions for the treatment of cancer, expanded its collaboration to increase the global availability of technetium-99m (Tc-99m),…
NorthStar Medical Radioisotopes is making organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business, the company announced today. “NorthStar is…
NorthStar Medical Radioisotopes received approval from the U.S. Food and Drug Administration (FDA) to produce the isotope Molybdenum-99 (Mo-99) from concentrated Mo-98 (cMo-98), the company announced recently. “This approval of production…
NorthStar Medical Radioisotopes, along with Wilmette, Ill.-based Monopar Therapeautics, have partnered with IsoTherapeutics Group to develop and manufacture Radio-Immuno-Therapeutics (RITs) for the potential treatment of severe COVID-19, the company announced recently….
